FoRx Therapeutics AG appoints Tarig Bashir as
Chief Executive Officer

Basel, Switzerland, 01 April, 2021 – FoRx Therapeutics, a recently incorporated privately-held company developing first-in-class compounds for cancer treatment, today announces the appointment of Tarig Bashir as Chief Executive Officer.

Tarig Bashir, PhD, is a Pharma and Biotech Executive with over 15 years of experience and leadership in cancer drug discovery, translational oncology and external innovation. During his career, he has led and overseen discovery-stage and preclinical oncology portfolios, led strategic partnerships with pharma and academia, and contributed significantly to clinical compound development. Tarig held positions of increasing responsibility in Oncology R&D at Organon/Schering-Plough, Johnson & Johnson and Ipsen. Most recently he was Executive Vice President Discovery at Proteros, where his responsibilities included new company building.
Tarig studied biology at the University of Würzburg and the State University of New York at Albany. He earned his PhD at the German Cancer Research Center (DKFZ) in Heidelberg and conducted his postdoctoral training at the New York University School of Medicine.

About FoRx Therapeutics
FoRx Therapeutics is a biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways activated in cancer. Drawing on discoveries by Prof. Thanos Halazonetis and Dr. Sotirios Sotiriou, FoRx was co-founded in 2019 with M Ventures, Novartis Venture Fund and Omega Funds along with Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE) and LSP (Life Sciences Partners). For more information, visit www.forxtherapeutics.com